Preview

Нервно-мышечные болезни

Расширенный поиск

Клиническая и диагностическая роль аутоантител к ганглиозидам периферических нервов: обзор литературы и собственные данные


https://doi.org/10.17650/2222-8721-2013-0-1-304-312

Полный текст:

Аннотация

Исследование антител к гликолипидам периферических нервов стало доступно для широкой практики во многих городах России. Показанием к проведению диагностического теста на определение антиганглиозидных антител является подозрение на синдром Гийена–Барре, синдром Миллера Фишера, энцефалит Бикерстаффа, хроническую воспалительную демиелинизирующую полинейропатию, мультифокальную моторную нейропатию. Показанием к определению анти-MAG-антител служит наличие у больного IgM-парапротеинемической полинейропатии. Зарубежный и отечественный опыт подтверждает необходимость включения этих иммунологических тестов в диагностический протокол исследования больных с подозрением на перечисленные дизиммунные заболевания нервной системы.

Об авторе

Н. А. Супонева
ФГБУ «Научный центр неврологии» РАМН, Москва
Россия


Список литературы

1. Latov N. Antibodies t o glycoconjugates in neuropathy and motor-neuron disease. Proc Brain Res 1994;101:295–303.

2. Chassande B., Leger J.M., Younes-Chennoufi et al. Peripheral neuropathy associated with IgM monoclonal gammopathy: correlations between M-protein antibody activity and clinical/electrophysiological features in 40 cases. Muscle Nerve 1998;21:55–62.

3. Kornberg A.J., Pestronk A. Chronic motor neuropathies: diagnosis, therapy, and pathogenesis. Ann Neurol 1995;37 Suppl 1:43–50.

4. Ilyas A.A., Quarles R.H., Dalakas M.C. et al. Monoclonal IgM in patient with paraproteinemic polyneuropathy binds to gangliosides containing disialosyl groups. Ann Neurol 1985;18:655–9.

5. Willison H.J., O’Learly, Veitch J. et al. The clinical and laboratory features of chronic sensory ataxic neuropathy with anti-disialosyl IgM antibodies. Brain 2001;24:1968–77.

6. Ilyas A.A., Willison H.J., Quarles R.H. et al. Serum antibodies to gangliosides in Guillain-Barre syndrome. Ann Neurol 1988;23:440–7.

7. Svennerholm L. Designation and schematic structure of gangliosides and allied glycosphingolipids. Prog Brain Res 1994;101:11–4.

8. Weller M., Stevens A., Sommer N. et al. Ganglioside antibodies: a lack of diagnostic specificity and clinical utility? J Neurol 1992;239:455–59.

9. Yuki N., Yoshino H., Sato S., Miyatake T. Acute axonal polyneuropathy associated with anti-GM1 antibodies following Campylobacter enteritis. Neurology 1990;40:1900–2.

10. Chiba A., Kusunoki S., Obata H. et al. Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barre syndrome: clinical and immunohistochemical studies. Neurology 1993;43:1911–7.

11. Gong Y., Lunn M.P., Heffer-Lauc M. et al. Localization of major gangliosides in the PNS: implications for immune neuropathies. J Periph Nerv Syst 2001;6:42.

12. Corbo M., Quattrini A., Latov N., Hays A.P. Localisation of GM1 and Gal(beta1-3)GalNAc antigenic determinants in peripheral nerve. Neurology 1993;43:809–14.

13. O’Hanlon G.M., Paterson G.J., Veitch J. et al. Mapping immunoreactive epitopes in the the human peripheral nervous system using human monoclonal anti-GM1 ganglioside antibodies. Acta Neuropathol (Berl) 1998;95:605–16.

14. Zielasek J., Ritter G., Magi S. et al. A comparative trial of anti-glyoconjugate antibody assays: IgM antibodies to GM1. J Neurol 1994;241:475–80.

15. Willison H., Yuki N. Peripheral neuropathies and anti-glycolipid antibodies. Brain 2002;125:2591–625.

16. Bansal A.S., Abdul-Karim B., Malik R.A. et al. IgM ganglioside GM1 antibodies in patients with autoimmune disease or neuropathy, and controls. J Clin Pathol 1994;47:300–2.

17. Nobile-Orazio E., Galia F., Terenghi F. et al. How useful are anti-neural IgM antibodies in the diagnosis of chronic immunemediated neuropathies? J Neurol Sci 2008;266:156–63.

18. Irie S., Saito T., Kanazawa N. et al. Relationship between Anti-ganglioside antibodies and clinical characteristics of Guillain-Barre syndrome. – Int Med 1997;36(9):607–12.

19. Kanzaki M., Kaida K., Ueda M. et al. Ganglioside complex containing GQ1b as targets in Miller Fisher and Guillain-Barre syndromes. J Neurol Neurosurg Psychiatry 2008;79:1148–52.

20. Fredman P., Vedeler C.A., Nyland H. et al. Antibodies in sera from patients with inflammatory demyelinating polyradiculoneuropathy react with ganglioside LM1 and sulfatide of peripheral nerve myelin. J Neurol 1991;238:75–9.

21. Yuki N., Tagawa Y., Handa S. Autoantibodies to peripheral nerve glycosphingolipids SPG, SLPG, and SGPG in Guillain-Barre syndrome and chronic inflammatory demyelinating polyneuropathy. J Neuroimmunol 1996;70:1–6.

22. Yako K., Kusunoki S., Kanazawa I. Serum antibody against a peripheral nerve myelin ganglioside, LM1, in Guillain-Barre syndrome. J Neurol Sci 1999;168:85–9.

23. Susuki K., Yuki N., Hirata K., Kuwabara S. Fine specificities of anti-LM1 IgG antibodies in Guillain-Barre syndrome. J Neurol Sci 2002;195:145–8.

24. Jacobs B.C., van Doorn P.A., Groeneveld J.H. et al. Cytomegalovirus infection and anti-GM2 antibodies in Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry 1997;62:641–3.

25. Walsh F.S., Cronin M., Koblar S. et al. Association between glycoconjugate antibodies and Campylobacter infection in patients with Guillain-Barre syndrome. J Neuroimmunol 1991;34:43–51.

26. Kornberg A.J., Pestronk A., Bieser K. et al. The clinical correlates of high-titer IgG anti- GM1 antiboies. Ann Neurol 1994;35:234–7.

27. Rees J.H., Gregson N.A., Hughes R.A. Anti-ganglioside GM1 antibodies in Guillain- Barre syndrome and their relationship to Campylobacter infection. Ann Neurol 1995;38: 809–16.

28. Jacobs B.C., van Doorn P.A., Schmitz P.I. et al. Campylobacter jejuni infections and anti- GM1 antibodies in Guillain-Barre syndrome. Ann Neurol 1996;40:181–7.

29. Hadden R.D., Cornblath D.R., Hughes R.A. et al. Electrophysiological classification of Guillain-Barre syndrome: clinical associations and outcome. Ann Neurol 1998;44:780–8.

30. Kuwabara S., Asahina M., Koga M. et al. IgG anti-GM1 antibody is associated with reversible conduction failure and axonal degeneration in Guillain-Barre syndrome. Ann Neurol 1998;44:202–8.

31. Kuwabara S., Ogawara K., Mizobuchi K. et al. Isolated absence of F waves and proximal axonal dysfunction in Guillain-Barre syndrome with antiganglioside antibodies. J Neurol Neurosurg Psychiatry 2000;68:191–5.

32. Yuki N., Ang C.W., Koga M. et al. Clinical features and response to treatment in Guillain-Barre syndrome associated with antibodies to GM1b ganglioside. Ann Neurol 2000;47:314–21.

33. Yuki N., Yamada M., Sato S. et al. Association of IgG anti-GD1a antibody with severe Guillain-Barre syndrome. Muscle Nerve 1993;16:642–7.

34. Kusunoki S., Iwamori M., Chiba A. et al. GM1b ia a new member of antigen for serum antibody in Guillain-Barre syndrome. Neurology 1996;47:237–42.

35. Ho T.W., Willison H.J., Nachamkin I. et al. Anti-GD1a antibody is associated with axonal but not demyelinating forms of Guillain-Barre syndrome. – Ann Neurol 1999;45:168–73.

36. Hao Q., Saida T., Yoshino H. et al. Anti-GalNAc-GD1a antibody-associated Guillain- Barre syndrome with predominantly distal weakness without cranial nerve impairment and sensory disturbance. Ann Neurol 1999;45:758–68.

37. Griffin J.W., Li C.Y., Ho T.W. et al. Pathology of the motor-sensory axonal Guillan-Barre syndrome. Ann Neurol 1996;39:17–28.

38. Yuki N., Kuwabara S., Koga M., Hirata K. Acute motor axonal neuropathy and acute motor-sensory axonal neuropathy share a common immunological profile. J Neurol Sci 1999;168:121–6.

39. Kusunoki S., Chiba A., Hitoshi S. et al. Anti-Gal-C antibody in autoimmune neuropathies subsequent to mycoplasma infection. Muscle Nerve 1995;18:409–13.

40. Quarles R.H. The spectrum and pathogenesis of antibody-mediated neuropathies. Neuroscientist 1997;3:195–204.

41. Carpo M., Pedotti R., Lolli F. et al. Clinical correlate and fine specificity of anti-GQ1b antibodies in peripheral neuropathy. J Neurol Sci 1998;155:186–91.

42. Paprounas K. Anti-GQ1b ganglioside antibody in peripheral nervous system disorders. Arch Neurol 2004;16:1013–16.

43. Notturno F., Capolare C., Uncini A. Acute sensory ataxic neuropathy with antibodies to GD1b gangliosides and prompt recovery. Muscle Nerve 2008;37:265–8.

44. Yuki N., Taki T., Kasama T. et al. A bacterium lipopolysaccharide that elicits Guillain-Barre syndrome has a GM1 ganglioside-like structure. J Exp Med 1993;178:1771–5.

45. Ang C.W., Endtz H.P., Jacobs B.C. et al. Campylobacter jejuni lipopolysaccharides from Guillain-Barre syndrome patients induce IgG anti-GM1 antibodies in rabbits. J neroimmunol 2000;104:133–8.

46. Prendergast M.M., Lastovica A.J., Moran A.P. Lipopolysaccharides from Campylobacter jejuni O:41 strains associated with Guillain-Barre syndrome exhibit mimicry of GM1 ganglioside. Infect Immun 1998;66:3649–55.

47. Takano H., Yuki N. Fisher’s syndrome associated with chickenpox and anti0GQ1b antibody [letter]. J Neurol 1995;242:255–6.

48. Yuki N., Taki T., Takahashi M. et al. Molecular mimicry between GQ1b ganglioside and lipopolysaccharides of Campylobacter jejuni isolated from patients with Fisher’s syndrome. Ann Neurol 1994;36:791–3.

49. Jacobs B.C., Hazenberg M.P., van Doorn P.A. et al. Cross-reactive antibodies against gangliosides and Campylobacter jejuni lipopolysaccharides in patients with Guillain- Barre or Miller Fisher syndrome. J Infect Dis 1997;175:729–33.

50. Goodyear C.S., O’Hanlon G.M., Plomp J.J. et al. Monoclonl antibodies raised against Guillain-Barre syndrome-associated Campylobacter jejuni lipopolysaccharides react with neuronal gangliosides and paralyze muscle-nerve preparations. J Clin Invest 1999;104:697–708.

51. Yuki N., Tagawa Y. Acute cytomegalovirus infection and IgM anti-GM2 antibody. J Neurol Sci 1998;154:14–7.

52. Chiba A., Kusunoki S., Obata H. et al. Ganglioside composition of the human cranial nerves, with specific reference to pathophysiology of Miller Fisher syndrome. Brain Res 1997;745:32–6.

53. Ang C.W., Jacobs B.C., Brandenburg A.H. et al. Cross-reactive antibodies against GM2 and CMV-infected fibroblasts in Guillain-Barre syndrome. – Neurology 2000;54:1453–8.

54. Kusunoki S., Tagawa H., Kanazawa I. Infection by Mycoplasma pneumonia anduces serum antibody against Gal-C [letter]. Muscle Nerve 1996;19:257–8.

55. Kitazawa K., Tagawa Y., Honda A., Yuki N. Guillain-Barre syndrome associated with IgG anti-GM1b antibody subsequent to Mycoplasma pneumonia infection. J Neurol Sci 1998;156:99–101.

56. Mori M., Kuwabara S., Miyake M. et al. Haemophilus influenzae infection and Guillain-Barre syndrome. Brain 2000;123:2171–8.

57. Koga M., Yuki N., Tai T. et al. Miller Fisher syndrome and Haemophilus influenza infection. Neurology 2001;57:686–91.

58. Пирадов М.А., Супонева Н.А. Синдром Гийена–Барре: клиника, диагностика и лечение. Руководство для врачей. М.: МЕД-ПРЕСС, 2011.

59. Супонева Н.А., Пирадов М.А. Внутривенная иммунотерапия в неврологии. М.: Горячая линия – Телеком, 2013.

60. Супонева Н.А., Пирадов М.А., Никитин С.С. и др. Патогенетическая и прогностическая роль аутоантител к ганглиозидам периферических нервов при синдроме Гийена–Барре. Анн клин и экспер неврологии, 2013;1:4–12.

61. Bollensen E., Steck A.J., Schachner M. Reactivity with peripheral myelin glycoprotein P0 in serum from patients with monoclonal IgM gammopathy and polyneuropathy. Neurology 1988;38:1266–70.

62. Клинические рекомендации по неврологии Европейской ассоциации неврологических сообществ. Пер. под ред. проф.С.С. Никитина. М.: АБВ-пресс, 2012.

63. Willison H.J., O’Hanlon G.M., Paterson G. et al. A somatically mutated human antiganglioside IgM antibody that induces experimental neuropathy in mice is encoded by the variable region heavy chain gene. J Clin Invest 1996;97:1155–64.

64. Nobile-Orasio E., Manfredini E., Carpo M. et al. Frequency and clinical correlates of anti-neural IgM antibodies in neuropathy associated with IgM monoclonal gammopathy. Ann Neurol 1994;36:416–24.

65. Freddo L., Yu R.K., Latov N. et al. Gangliosides GM1 and GD1b are antigens for IgM M-protein in a patient with motor neuron disease. Neurology 1986;36:454–8.

66. Kuwahara M., Suzuki S., Takada K., Kusunoki S. Antibodies to LM1 and LM1-containing ganglioside complexes in Guillain-Barré syndrome and chronicinflamm atory demyelinating polyneuropathy. J Neuroimmunol. 2011;239(1–2):87–90.

67. Remiche G., Kentos A., Mavroudakis N. Distal acquired demyelinating symmetric neuropathy associated with anti-GM1 antibodies: is this a CIDP variant? Acta Neurol Belg 2010;110(1):103–6.

68. Шевченко А.В. Хронические воспалительные демиелинизирующие полиневропатии у детей (клиника, диагностика, дифференциальная диагностика). Автореф. дис. … канд. мед. наук. М., 2007.

69. Pestronk A., Cornblath D.R., Ilyas A.A. et al. A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside. Ann Neurol 1988;24:73–8.

70. Van Schaik I.N., Bossuyt P.M., Brand A., Vermeulen M. Diagnostic value of GM1 antibodies in motor-neuron disorders and neuropathies: a meta-analysis. Neurology 1995;45:1570–7.

71. O’Hanlon G.M., Veitch J., Gallardo E. et al. Peripheral neuropathy associated with anti-GM2 ganglioside antibodies: clinical and immunopathological studies. Autoimmunity 2000;32:133–44.

72. Jacobs B.C., Rothbarth P.H., van der Meche et al. The spectrum of antecedent infections in Guillain-Barre syndrome: a casecontrol study. Neurology 1998;51:1110–5.

73. Ахмеджанова Л.Т. Клинико-иммунологическая характеристика хронических демиелинизирующих полиневропатий. Автореф. дис. … канд. мед. наук. М., 2008.

74. Leger J.M., Chassande B., Musset L. et al. Intravenous immunoglobulin therapy in multifocal motor neuropathy: a doubleblind, placebo-controlled study. Brain 2001;124:145–53.


Для цитирования:


Супонева Н.А. Клиническая и диагностическая роль аутоантител к ганглиозидам периферических нервов: обзор литературы и собственные данные. Нервно-мышечные болезни. 2013;(1):26-34. https://doi.org/10.17650/2222-8721-2013-0-1-304-312

For citation:


Suponeva N.A. Clinical and diagnostic role of autoantibodies to gangliosides of peripheral nerves: literature review and own expirience. Neuromuscular Diseases. 2013;(1):26-34. (In Russ.) https://doi.org/10.17650/2222-8721-2013-0-1-304-312

Просмотров: 231


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2222-8721 (Print)
ISSN 2413-0443 (Online)